News

Deal Announcements

Laguna Pharma Closes Series B Venture Capital Round

Wednesday, February 18, 2015 5:48:00 AM PDT | VentureDeal
   La Jolla, California  --  Laguna Pharmaceuticals, formerly ChanRx, has received $30 million in its second round of institutional venture capital funding.

Laguna is developing vanoxerine for the treatment of atrial fibrillation and atrial flutter.

Lead investors in the round were Versant Ventures and Frazier Healthcare Ventures.

Additional investors were Sante Ventures and BioMed Ventures.

The company said it would use the proceeds to progress its phase 3 clinical development for its lead compound vanoxerine.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1